Tilray Posts Record Q1 Revenue of $257M, Reaffirms FY27 EBITDA Guidance
TLRY is trading near its 52-week low of $3.54 (4.5% above the low).
Summary
Tilray reported record Q1 FY2027 revenue of $257.1M (+23% YoY) and reaffirmed FY27 adjusted EBITDA guidance of $68M–$75M, while reducing debt by $42M and reaching a net cash position.
Updates
· Reuters — Analysts expected a loss of 20 cents per share on revenue of $267.46 million; shares fell 0.9% this quarter and 58.9% year-to-date.
- Q1 adjusted loss of 32 cents per share was lower than prior year's breakeven EPS.
- Wall Street's expected EPS range for the quarter was -32 cents to -7 cents.
- Company reported a quarterly net loss of $43.14 million.
Key Events · Earnings and Guidance · TLRY
-
Record Q1 Revenue
Net revenue rose 23% YoY to $257.1M, with gross margin expanding ~300 bps to 30%.
-
Beverage Segment Surge
Beverage revenue jumped 82% to $101.5M; BrewDog achieved profitability in the quarter.
-
Adjusted EBITDA and Net Loss
Adjusted EBITDA was $9.2M vs $10.2M prior year; net loss of $40.0M driven by non-cash charges.
-
FY27 Guidance Reaffirmed
Company reaffirmed FY2027 adjusted EBITDA guidance of $68M–$75M, implying double-digit growth.
Analysis · TLRY · Life Sciences
Record first-quarter revenue of $257.1 million, up 23% year-over-year, underscores Tilray's accelerating momentum, with gross margin expanding roughly 300 basis points to 30%. The beverage segment stood out, growing 82% to $101.5 million and turning BrewDog profitable. A $40 million net loss driven by non-cash charges contrasted with adjusted EBITDA of $9.2 million, down from $10.2 million a year earlier. Management reaffirmed full-year adjusted EBITDA guidance of $68 million to $75 million, signaling confidence in the back-half-weighted fiscal year. The balance sheet strengthened with $42 million of debt reduction and a net cash position, providing flexibility as recent acquisitions are integrated.
How filings like this one have moved
In the 30 days to Oct 12, 2026, 28.9% of the 1436 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLRY was trading at $3.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $549M. The 52-week trading range was $3.54 to $23.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.